Let’s Settle This: Is Psyllium Husk Really ‘Nature’s Ozempic’?
psyllium husk GI surgeon Dr Karan Rajan seems pretty fond of psyllium husk. In a video posted last year, he extolled the virtues of the cheap, soluble fibre-rich supplement, explaining it can help to cure both constipation and diarrhoea. It is also, he added, pointing to this 2021 review of studies, “useful in some types of IBS.” […]
Diabetes drug cuts migraines in half by targeting brain pressure
A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic migraines who took liraglutide, a GLP-1 receptor agonist, experienced over 50% fewer headache days and significantly improved daily functioning without meaningful weight loss. Researchers believe the drug s ability to lower brain fluid pressure […]
American College of Cardiology Recommends GLP-1s as First Line Treatment Option
What You Should Know: – The American College of Cardiology (ACC) has published a new Concise Clinical Guidance (CCG) report, providing a comprehensive framework for clinicians to medically manage obesity using the “ever-expanding set of tools to assist patients in diagnosis, weight reduction, and CVD risk mitigation.” – The new guidance, published in the Journal […]
From blood sugar to brain relief: GLP-1 therapy linked to lower migraine frequency
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.
Weight loss jab could be used to treat migraines
GLP-1 drug liraglutide could become a new treatment option for the estimated one in seven people worldwide who live with migraines
[Comment] GLP-1 and amylin receptor multiagonism with amycretin for obesity management
As is now well known, obesity and excess adiposity is a global health issue, burdening people with multiple comorbidities such as type 2 diabetes, cardiovascular disease, musculoskeletal diseases, cancer, and sleep apnoea.1 The treatment of obesity and its comorbidities has been revolutionised in the past 5–10 years with the introduction of GLP-1 receptor monoagonists such […]
[Articles] Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
In people with overweight or obesity, once-weekly subcutaneous amycretin up to 60 mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists. Although a high frequency of gastrointestinal events was reported, rates were similar to those seen in early-phase studies of these molecules. These results support further investigation into the weight loss […]
[Articles] Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
In people with overweight or obesity, amycretin appeared safe and tolerable. Results from this first-in-human, phase 1 study support further investigation of the weight loss properties of amycretin.
STAT+: Full data on Novo Nordisk’s new amylin drug raise dosing questions
CHICAGO — Novo Nordisk’s next-generation obesity injection targeting the amylin hormone showed substantial weight loss in an early study, but similar efficacy across different doses and high rates of side effects raise questions about which dose Novo will pursue going forward. In the Phase 1/2 study testing the drug, called amycretin, patients on the highest […]
Comment on: The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
Dear Editor,